Chronic PainNCT04601454
DTM (TM) Spinal Cord Stimulation (SCS) Study
A study testing Spinal Cord Stimulation System in people with Chronic Pain, run by MedtronicNeuro at 13 sites in United States.
Trial summary
Prospective, multi-center, open-label, post-market study to evaluate the efficacy and energy use of a low energy DTM™ (DTM-LE) SCS therapy for pain relief. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Pain
- What is being tested?
- Spinal Cord Stimulation System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 57 participants
- Where
- 13 sitesUnited States
- Study dates
- 5 Nov 2020to 25 Aug 2022
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older
- Willing and able to provide signed and dated informed consent
- Capable of comprehending and consenting in English
- Candidate per labeling for an SCS system as an aid in the management of chronic, intractable pain of the trunk and/or limbs
- Has moderate to severe back and leg pain
- Stable pain medications for back and leg pain for at least 28 days prior to enrollment
Show all 9Show fewer
- Willing and able to comply with all study procedures and visits
- Willing and able to not increase their pain medications through the 3-Month visit
- Able to differentiate between pain associated with the indication for SCS implant and other types of pain
Who cannot join
- Previously trialed or implanted with a stimulator or intrathecal drug delivery system
- Expected to be inaccessible for follow-up
- Current diagnosis of moderate to severe central lumbar spinal stenosis with symptomatic neurogenic claudication
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results
- If female, is pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study
- Has untreated major psychiatric comorbidity
Show all 9Show fewer
- Serious drug-related behavioral issues
- Unable to achieve supine or prone position
- Classified as vulnerable or requires a legally authorized representative (LAR)
Trial locations and contacts
13 sites in 1 country.
13 sites in 1 country
United States13 sites
Goodman Campbell Brain and Spine
Carmel, Indiana, 46032
The Woodlands Pain Institute
Conroe, Texas, 77384
Carolinas Pain Center
Huntersville, North Carolina, 28078
Center for Interventional Pain and Spine
Lancaster, Pennsylvania, 17604
Oklahoma Pain Physicians
Oklahoma City, Oklahoma, 73120
The Burkhart Research Institute for Orthopaedics
San Antonio, Texas, 78216
Pain Diagnostics and Interventional Care
Sewickley, Pennsylvania, 15143
Sprintz Center for Pain
Shenandoah, Texas, 77384
Drez One LLC
Somerset, Kentucky, 42503
Delaware Valley Pain and Spine Institute
Trevose, Pennsylvania, 19053
Precision Spine Care
Tyler, Texas, 75701
IPM Medical Group
Walnut Creek, California, 94598
Novant Health
Winston-Salem, North Carolina, 27103
About this study
Official title: DTM (TM) Low Energy Spinal Cord Stimulation (SCS) Study
Prospective, multi-center, open-label, post-market study to evaluate the efficacy and energy use of a low energy DTM™ (DTM-LE) SCS therapy for pain relief.
Read the detailed description
This post market study will measure the following:
- Visual Analog Scale
- Programming Parameters
- Conditions
- Chronic Pain
- Being tested
- Spinal Cord Stimulation System
- Medical subject headings
- Chronic Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Spinal Cord Stimulation SystemDevice
Also called Medtronic Intellis AdaptiveStim Neurostimulation System
Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
| Study group | Role | What they receive |
|---|---|---|
| Spinal Cord Stimulation | Experimental | Enrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters. Receives: Device: Spinal Cord Stimulation System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual Analog Scale (VAS)
To characterize changes in overall (back and leg) pain intensity. Pain will be assessed using a VAS (0-10 cm) with 0 cm meaning "no pain" and 10 cm meaning "worst pain imaginable". Overall pain is defined as a combination of back and leg pain, but not pain from other body parts. Subjects will be asked to report their average pain intensity that is related to their SCS device treatment "in the last 24 hours" by marking a line perpendicular to the VAS line at the point that represents their pain intensity.
Measured: Baseline to 3 Months
Secondary outcomes (4)
Programming Parameters: Frequency in Hertz (Hz)
To characterize programming parameters associated with energy use. Subject's programmed frequency settings will be summarized using the minimum and maximum frequency across all subjects. Programming methodology for this study included up to four active program frequencies for each subject.
Measured: 12 Month
Programming Parameters: Pulse Width in Microseconds (µs)
To characterize programming parameters associated with energy use. Subject's programmed Pulse Width settings will be summarized using the minimum and maximum Pulse Width across all subjects. Programming methodology for this study included up to four active program frequencies for each subject.
Measured: 12 Month
Programming Parameters: Amplitude (Intensity) in Milliamp (mA)
To characterize programming parameters associated with energy use. Subject's programmed Amplitude settings will be summarized using the minimum and maximum Amplitude across all subjects. Programming methodology for this study included up to four active program frequencies for each subject.
Measured: 12 Month
Programming Parameters: Impedance Range in Ohms
To characterize programming parameters associated with energy use. Subject's programmed Impedance settings will be summarized using the minimum and maximum Impedance across all subjects. Programming methodology for this study included up to four active program frequencies for each subject.
Measured: 12 Month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2020
- Study start5 Nov 2020
- Primary completion29 Nov 2021
- Study completion25 Aug 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Chronic PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 57 participants (actual)
Sponsor and investigators
- Lead sponsor
- MedtronicNeuro
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Restorative Therapies Group Restorative Therapies Group, Study director, Medtronic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04601454
- Sponsor's protocol ID
- MDT20042
- Status last verified
- Feb 2023
- First submitted
- 5 Oct 2020
- Last updated
- 24 Feb 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DTM (TM) Low Energy Spinal Cord Stimulation (SCS) Study
- ClinicalTrials.gov ID
- NCT04601454
- Acronym / sponsor ID
- MDT20042
- Conditions
- Chronic Pain
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 57 participants (actual)
- Lead sponsor
- MedtronicNeuroIndustry (pharma, biotech, devices)
- Study start
- 5 Nov 2020 (actual)
- Primary completion
- 29 Nov 2021 (actual)
- Study completion
- 25 Aug 2022 (actual)
- First posted
- 23 Oct 2020 (actual)
- Results
- Posted 24 Feb 2023
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective, multi-center, open-label, post-market study to evaluate the efficacy and energy use of a low energy DTM™ (DTM-LE) SCS therapy for pain relief.
Detailed description
This post market study will measure the following:
- Visual Analog Scale
- Programming Parameters
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Spinal Cord Stimulation | Experimental | Device: Spinal Cord Stimulation SystemEnrolled subjects are implanted with a rechargeable spinal cord stimulation system that is activated and programmed to on-label parameters. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- 18 years of age or older
- Willing and able to provide signed and dated informed consent
- Capable of comprehending and consenting in English
- Candidate per labeling for an SCS system as an aid in the management of chronic, intractable pain of the trunk and/or limbs
- Has moderate to severe back and leg pain
Key exclusion criteria (9 listed)
- Previously trialed or implanted with a stimulator or intrathecal drug delivery system
- Expected to be inaccessible for follow-up
- Current diagnosis of moderate to severe central lumbar spinal stenosis with symptomatic neurogenic claudication
- Currently enrolled or planning to enroll in an interventional clinical study that could potentially confound the study results
- If female, is pregnant or is of child-bearing potential and unwilling to use a medically acceptable form of birth control during the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Spinal Cord Stimulation SystemAlso: Medtronic Intellis AdaptiveStim Neurostimulation SystemRechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters. | Device | Spinal Cord Stimulation |
Primary outcome
Visual Analog Scale (VAS)
Time frame: Baseline to 3 Months
To characterize changes in overall (back and leg) pain intensity. Pain will be assessed using a VAS (0-10 cm) with 0 cm meaning "no pain" and 10 cm meaning "worst pain imaginable". Overall pain is defined as a combination of back and leg pain, but not pain from other body parts. Subjects will be asked to report their average pain intensity that is related to their SCS device treatment "in the last 24 hours" by marking a line perpendicular to the VAS line at the point that represents their pain intensity.
4 secondary outcomes
Programming Parameters: Frequency in Hertz (Hz)
Time frame: 12 Month
Programming Parameters: Pulse Width in Microseconds (µs)
Time frame: 12 Month
Programming Parameters: Amplitude (Intensity) in Milliamp (mA)
Time frame: 12 Month
Programming Parameters: Impedance Range in Ohms
Time frame: 12 Month
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Chronic Pain
Recruiting
Studying Melatonin and Recovery in Teens
Juvenile; Scoliosis, Scoliosis Idiopathic
Enrolling by invitation
Efficacy of a Chronic Pain Treatment Prior to Gender-affirming Surgery
Pain Catastrophizing, Pain, Chronic
Recruiting
Uncovering the Mechanism of Pain Relief by Peripheral Transcutaneous Magnetic Stimulation
Post-Surgical Pain, Chronic, Post-traumatic Pain, Chronic
Recruiting
Focused Ultrasound Stimulation for the Treatment of Chronic Pain
Chronic Pain
Not yet recruiting
Multicomponent Exercise and Pain Science Education for Fall Prevention in Older Adults With Chronic Musculoskeletal Pain (MovePainFall)
Chronic Pain, Musculoskeletal Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Restorative Therapies Group Restorative Therapies Group study director
Medtronic
13 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Spinal Cord Stimulation System in people with Chronic Pain, run by MedtronicNeuro at 13 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Feb 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual Analog Scale (VAS) (time frame: Baseline to 3 Months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2023; AzTrials last refreshed its copy on 28 Oct 2026.